LIFE, US0021202025

aTyr Pharma implements one-for-forty split. aTyr Pharma stock is valued at USD 11.3 million

Published on 10/27/2026 at 19:14 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

On October 19, ATYR2810 entered preclinical osteosarcoma research. aTyr Pharma stock costs EUR 0.10 on October 27, 2026.

Reverse split and research update

aTyr Pharma filed a one-for-forty reverse split amendment on October 27, 2026.
ATYR2810 entered preclinical pediatric osteosarcoma research on October 19, 2026.
aTyr Pharma stock costs EUR 0.10 at Lang & Schwarz on October 27, 2026 at 7:10 p.m. CEST.

LIFE, US0021202025, Illustration mit AI erstellt.

aTyr Pharma (ISIN US0021202025) filed an amendment implementing a one-for-forty reverse stock split on October 27, 2026, effective October 28, 2026, according to TipRanks. The company stock costs EUR 0.10 at Lang & Schwarz on October 27, 2026 at 7:10 p.m. CEST.

Split terms reset the share count

The amendment reduces the number of common shares from 100.5 million to 2.5 million, while authorized share capital remains unchanged, TipRanks reported on October 27, 2026. Existing shares, options, restricted stock units and warrants receive proportional adjustments, and fractional shares are rounded up to whole shares.

ATYR2810 stays in preclinical research

The company expanded ATYR2810 research into pediatric osteosarcoma through a collaboration with Albert Einstein College of Medicine and Montefiore Einstein on October 19, 2026. StockTitan reported that the antibody targets the neuropilin-2 receptor and remains in preclinical development. The program has completed GLP toxicology testing in non-human primates and cGMP manufacturing.

Nasdaq valuation remains small

aTyr Pharma had a market capitalization of USD 11.3 million and a volume of 6,658,978 shares as of October 27, 2026. Its Nasdaq quote was USD 0.12 at 2:13 p.m. EDT, while the 52-week range stood at USD 0.10 to USD 1.11. The euro quotation and the Nasdaq quotation are separate venue observations.

When does trading change?

TipRanks reported that split-adjusted trading on Nasdaq is scheduled to begin on October 29, 2026, under the ATYR ticker. The company describes efzofitimod as its lead therapeutic candidate for interstitial lung disease and identifies the Phase 2 EFZO-CONNECT study as ongoing in its investor materials, available from aTyr Pharma.

Stock price and split timing

The reverse split changes the number of shares and the per-share presentation, but it does not by itself change the ownership percentage of existing holders. The next trading date tied to the corporate action is October 29, 2026.

The further course of trading is shown by the continuously updated real-time quote of aTyr Pharma stock.